Squarepoint
PYXS icon

Squarepoint’s Pyxis Oncology PYXS Stock Holding History

Squarepoint’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.6K Buy
+17,537
New +$26.4K ﹤0.01% 4172
2025
Q3 		– Sell
-35,428
Closed -$39K – 4867
2025
Q2 		$39K Buy
35,428
+20,514
+138% +$23.1K ﹤0.01% 4340
2025
Q1 		$14.6K Buy
+14,914
New +$19.9K ﹤0.01% 4452
2024
Q2 		– Sell
-68,358
Closed -$291K – 4535
2024
Q1 		$291K Buy
+68,358
New +$287K ﹤0.01% 3411
2023
Q4 		– Sell
-22,556
Closed -$44.9K – 4396
2023
Q3 		$44.9K Buy
+22,556
New +$52.3K ﹤0.01% 3648
2023
Q2 		– Sell
-37,945
Closed -$152K – 3918
2023
Q1 		$152K Buy
+37,945
New +$75.8K ﹤0.01% 2887
2022
Q1 		– Sell
-31,328
Closed -$344K – 3383
2021
Q4 		$344K Buy
+31,328
New +$359K ﹤0.01% 2374

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's PYXS Position: Q1 2026 in Review

Squarepoint opened a new position in Pyxis Oncology (PYXS) in Q1 2026: 17,537 shares worth $25.6K. The stake represents ﹤0.01% of the portfolio and ranks #4172 among its holdings. This is a return to the name: Squarepoint previously reported a position in PYXS as recently as Q2 2025.

Squarepoint first reported a position in PYXS in Q4 2021 and has held it in 7 quarters since. The position peaked at $344K in Q4 2021. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Squarepoint held 17,537 shares of Pyxis Oncology worth $25.6K as of Q1 2026.
  • Pyxis Oncology was a new Squarepoint position in Q1 2026.
  • Pyxis Oncology made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4172 holding.
  • Squarepoint first reported a position in Pyxis Oncology in Q4 2021 and has held it in 7 quarters since.
  • Squarepoint's Pyxis Oncology position peaked at $344K in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.